Investigation on Risk Factors of Rheumatoid Arthritis Related Interstitial Lung Disease

Last updated: September 7, 2023
Sponsor: First Affiliated Hospital of Chongqing Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rheumatoid Arthritis

Joint Injuries

Treatment

diagnosis of Interstitial lung disease

Clinical Study ID

NCT06036537
1stChongqingMU123
  • Ages > 18
  • All Genders

Study Summary

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, characterized by chronic inflammatory bone and cartilage destruction. Although treatment including anti-tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor antibodies has been successful, only 20% to 30% of patients have achieved complete remission. Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis (RA). Approximately 5-10% of RA patients have clinically significant rheumatoid arthritis associated interstitial lung disease (RA-ILD), with a mortality rate of 2-10 times that of RA-non ILD patients. The median survival after diagnosis is between 3-8 years. Although there are multiple biomarkers for RA-ILD, such as anti citrullinated protein antibody (ACPA), MUC5B mutant gene, KL-6, etc., none of these biomarkers can reliably predict the disease and prognostic risk of RA-ILD. Therefore, improving the prediction of RA complicated with ILD and exploring risk factors for the progression and prognosis of RA-ILD can contribute to early diagnosis and treatment, and is of great significance in preventing RA lung injury and death.

This study aims to screen differential serum biomarkers between RA patients and RA-ILD patients through prospective cohort studies, to explore whether these differential serum biomarkers are a risk factor for RA patients complicated with ILD, and whether they affect the clinical prognosis of RA-ILD patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Diagnosis of rheumatoid arthritis patients based on the 2010 ACR/EULAR RA classificationcriteria; 2. age ≥18 years; 3. Interstitial lung disease was diagnosed by lung highresolution computed tomography (HRCT)

Exclusion

Exclusion Criteria:

  1. age <years; 2. Being treated with urate-lowering medications; 3. Other systemic/organspecific autoimmune diseases other than rheumatoid arthritis (such as SLE, ANCA associatedvasculitis, pSS, SSc, myositis, etc.); 4.Tumor, pulmonary tuberculosis, glomerularfiltration rate less than 30ml/min/1.73m2

Study Design

Total Participants: 1200
Treatment Group(s): 1
Primary Treatment: diagnosis of Interstitial lung disease
Phase:
Study Start date:
June 01, 2023
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • Chongqing General Hospital

    Chongqing, Chongqing 401147
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.